Ventegra, LLC

Situation 

Injectable medications are a complex challenge for many payors. Historically, these medications have been treated as a “medical” expense but, as many providers know, injectable medications are just another dosage form of a drug. Drugs are commonly managed under a pharmacy benefit. Thus, the confusion today as patients and providers grapple with balancing injectable and oral medication treatment alternatives. Different copayments, treatment guidelines, benefit plans, out-of-pocket requirements, and delivery systems with conflicting information coming out of medical and pharmacy systems add to the confusion.

Solution

The Ventegra Injectable Program (“VIP”) embraces an acquisition cost-based injectable distribution solution that allows a payor to get the actual net cost of these expensive pharmaceuticals. There isn’t any incentive to “float the dose” or dispense more product to patients because our program’s dispensing fees are not tied to the volume of the prescription. There is also no hidden margin between what the distribution center charges the patient versus what is charged on the claim to the payor. Ventegra offers true transparency on all discounts, rebates and other fees negotiated with manufacturers and/or suppliers of injectable drugs. These price concessions may be incorporated into the administration of the benefit design so that payors, as well as patients needing injectable drugs, realize their fair share of the savings. VIP guarantees to do its share to help reduce the high cost of injectable drugs.

Better Health Lower Costs

AWP minus 22% on acquisition cost of drugs (AWP minus 30%+ when rebates/discounts are factored). Full transparency guaranteed in the contract!